NEWS

Sensome begins human trial for its AI-powered stroke guidewire

Paris, France - September 13th, 2021 - Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today that Gold Coast University Hospital (GCUH) in Australia enrolled the first patients in the Company’s CLOT OUT first-in-human study evaluating safety and performance of the Clotild® Smart Guidewire System in large-vessel acute ischemic stroke patients.

Treating an Acom aneurysm using flow diversion

Transmission of 2 live INR procedures using robotics

Wallaby Medical partners with Brainomix to bring the most comprehensive...

SHANGHAI, CHINA – August 26, 2021 -  Wallaby Medical (“Wallaby”), a rapidly growing medical device company focused on developing and commercializing medical device products for treating stroke, and Brainomix Limited (“Brainomix”), a UK-headquartered company that specializes in the creation of AI-powered imaging biomarkers and software solutions that enable precision medicine for better treatment decisions, announced the signing of a new distribution agreement. As part of the agreement, Wallaby will distribute Brainomix’s e-Stroke software to stroke centres across Greater China.

Cerebellar AVM with occipital artery and PICA feeding

Following its acceptance into Frontiers in Neurology, phenox is pleased...

In  the paper by Serna Candel et. al* , the outcomes of pRESET 4x20 were examined against the outcomes of cases where pRESET 5x40 was the stentriever of choice. The results speak for themselves and it is clear that the theory of longer stentrievers leading to better patient outcomes is proven here once again.

Aneurysm on the left ICA in carotid cave segment

Glomus transarterial embolization with EVOH

Arterial and venous approach for treating a complex AVM

Philips announces first patient enrolled in the WE-TRUST global multicen...

Amsterdam, the Netherlands –  Royal Philips  (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the first patient has been enrolled in the WE-TRUST study at Vall d’Hebron University Hospital, Barcelona, Spain, marking the official start of this major multicenter randomized controlled trial to assess if the  Direct to Angio Suite  workflow can improve outcomes for early time-window stroke patients (less than six hours after stroke onset).